Yupelri is an inhalation solution used to treat bronchopulmonary dysplasia (BPD) in preterm infants [1]. It is administered at a dosage of 175 mcg in 3 ml [1].
What is Yupelri used for in infants?
Yupelri, an inhalation solution of 175 mcg per 3 ml, is indicated for the treatment of bronchopulmonary dysplasia in preterm infants [1].
How is Yupelri administered?
Yupelri is administered as an inhalation solution. The prescribed dose is 175 mcg in 3 ml for the treatment of bronchopulmonary dysplasia in preterm infants [1].
What is the dosage for Yupelri?
The dosage for Yupelri is 175 mcg per 3 ml of inhalation solution [1].
Are there other uses for Yupelri?
Currently, Yupelri's indication is for the treatment of bronchopulmonary dysplasia in preterm infants [1]. Information on other uses is not provided.
What is bronchopulmonary dysplasia?
Bronchopulmonary dysplasia (BPD) is a chronic lung disease that affects newborns, particularly premature infants, who have received prolonged mechanical ventilation and oxygen therapy [2]. It is characterized by airway and alveolar damage [2].
Are there any known side effects of Yupelri?
Specific side effects of Yupelri are not detailed in the provided information.
What is the active ingredient in Yupelri?
The active ingredient is not explicitly named, but the formulation is an inhalation solution of 175 mcg in 3 ml [1].
Who manufactures Yupelri?
Information regarding the manufacturer of Yupelri is not provided.
When does the patent for Yupelri expire?
Information on Yupelri's patent expiry is not available. For patent status and expiry dates of specific drugs, resources like DrugPatentWatch.com may be helpful [3].
Are there alternative treatments for bronchopulmonary dysplasia?
While Yupelri is indicated for BPD, information on alternative treatments is not provided.
---
Sources
[1] Yupelri. (n.d.). Retrieved from https://www.yupelri.com/
[2] Bronchopulmonary Dysplasia. (n.d.). Retrieved from https://www.lung.org/lung-health-diseases/lung-disease-lookup/bronchopulmonary-dysplasia
[3] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/